- Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry
-
Jun Sik Yoon, Han Ah Lee, Hwi Young Kim, Dong Hyun Sinn, Dong Ho Lee, Suk Kyun Hong, Ju-Yeon Cho, Jonggi Choi, Young Chang, Hyun-Joo Kong, Eunyang Kim, Young-Joo Won, Jeong-Hoon Lee
-
J Liver Cancer. 2021;21(1):58-68. Published online March 31, 2021
-
DOI: https://doi.org/10.17998/jlc.21.1.58
-
-
6,602
Views
-
265
Downloads
-
18
Citations
-
Abstract
PDFSupplementary Material
- Background/Aim
s: Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading cause of cancer-related death in Korea. This study evaluated the characteristics of Korean patients newly diagnosed with HCC in 2015.
Methods Data from the Korean Primary Liver Cancer Registry (KPLCR), a representative sample of patients newly diagnosed with HCC in Korea, were analyzed. A total of 1,558 patients with HCC registered in the KPLCR in 2015 were investigated.
Results The median age was 61.0 years (interquartile range, 54.0-70.0 years), and men accounted for 79.7% of the subjects. Hepatitis B virus infection was the most common underlying liver disease (58.1%). According to the Barcelona Clinic Liver Cancer (BCLC) staging system, stage 0, A, B, C, and D HCCs accounted for 14.2%, 31.5%, 7.6%, 39.0%, and 7.8% of patients, respectively. Transarterial therapy (32.1%) was the most commonly performed initial treatment, followed by surgical resection (23.2%), best supportive care (20.2%), and local ablation therapy (10.7%). Overall, 34.5% of patients were treated in accordance with the BCLC guidelines: 59.2% in stage 0/A, 48.4% in stage B, 18.1% in stage C, and 71.6% in stage D. The 1-, 3-, and 5-year OS rates were 67.1%, 50.9%, and 27.0%, respectively.
Conclusions In 2015, approximately 45% of Korean HCC cases were diagnosed at a very early or early stage, and 35% of patients underwent potentially curative initial treatment. BCLC guidance was followed in 34.5% of patients; in patients with stage B or C disease, there was relatively low adherence.
-
Citations
Citations to this article as recorded by
- Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study
Bo Hyun Kim, Hee Chul Park, Tae Hyun Kim, Young-Hwan Koh, Jung Yong Hong, Yuri Cho, Dong Hyun Sinn, Boram Park, Joong-Won Park JHEP Reports.2024; 6(4): 100991. CrossRef - Identification of patients with favorable prognosis after resection in intermediate-stage-hepatocellular carcinoma
Han Ah Lee, Minjong Lee, Jeong-Ju Yoo, Ho Soo Chun, Yewan Park, Hwi Young Kim, Tae Hun Kim, Yeon Seok Seo, Dong Hyun Sinn International Journal of Surgery.2024; 110(2): 1008. CrossRef - Factors associated with the survival outcomes of patients with untreated hepatocellular carcinoma: An analysis of nationwide data
Min Jung Kwon, Soy Chang, Ji Hoon Kim, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung Frontiers in Oncology.2023;[Epub] CrossRef - The imitator of immune-tolerant chronic hepatitis B: A killer in disguise
Moon Haeng Hur, Jeong-Hoon Lee Clinical and Molecular Hepatology.2023; 29(2): 363. CrossRef - Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study
Sun Hong Yoo, Soon Sun Kim, Sang Gyune Kim, Jung Hyun Kwon, Han-Ah Lee, Yeon Seok Seo, Young Kul Jung, Hyung Joon Yim, Do Seon Song, Seong Hee Kang, Moon Young Kim, Young-Hwan Ahn, Jieun Han, Young Seok Kim, Young Chang, Soung Won Jeong, Jae Young Jang, J Journal of Liver Cancer.2023; 23(1): 189. CrossRef - A Case of Transverse Myelitis Following Treatment with Atezolizumab for Advanced Hepatocellular Carcinoma
Kyung Han Kim, Yang-Hyun Baek, Yeo Wool Kang, Byeol-A Yoon, Sang Yi Moon The Korean Journal of Gastroenterology.2023; 82(1): 35. CrossRef - Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study
Ji Kim, Hee-Chul Nam, Chang-Wook Kim, Hee Cho, Jae-Sung Yoo, Ji Han, Jeong Jang, Jong Choi, Seung Yoon, Hyun Yang, Si Bae, Suho Kim, Jung Oh, Ho Chun, Chang Jeon, Jaegyoon Ahn, Pil Sung Cancers.2023; 15(17): 4233. CrossRef - A nationwide study on the current treatment status and natural prognosis of hepatocellular carcinoma in elderly
Jeong-Ju Yoo, Jayoun Lee, Gi Hong Choi, Min Woo Lee, Dong Ah Park Scientific Reports.2023;[Epub] CrossRef - Modeling the Risk of Liver Cancer in Adults: A Machine Learning Investigation into the Role of Obesity and Overweight
Bah Karamo, Bah Adama Ns , Jallow Amadou Wurry Archives of Pathology and Clinical Research.2023; 7(1): 034. CrossRef - Surgical resection versus ablation for early hepatocellular carcinoma: The debate is still open
Bo Hyun Kim Clinical and Molecular Hepatology.2022; 28(2): 174. CrossRef - Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area
Bo Hyun Kim, Dahhay Lee, Kyu-Won Jung, Young-Joo Won, Hyunsoon Cho Clinical and Molecular Hepatology.2022; 28(2): 242. CrossRef - Impact of tumor size on hepatectomy outcomes in hepatocellular carcinoma: a nationwide propensity score matching analysis
Suk Kyun Hong, Kwang-Woong Lee, Sola Lee, Su young Hong, Sanggyun Suh, Eui Soo Han, YoungRok Choi, Nam-Joon Yi, Kyung-Suk Suh Annals of Surgical Treatment and Research.2022; 102(4): 193. CrossRef - Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: A meta-analysis
Han Ah Lee, Yeon Seok Seo, In-Soo Shin, Won Sup Yoon, Hye Yoon Lee, Chai Hong Rim International Journal of Surgery.2022; 104: 106753. CrossRef - Yoon et al. Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry
Jeong-Hoon Lee Journal of Liver Cancer.2022; 22(2): 207. CrossRef - Surveillance for hepatocellular carcinoma: It is time to move forward
Bo Hyun Kim, Yuri Cho, Joong-Won Park Clinical and Molecular Hepatology.2022; 28(4): 810. CrossRef - Treatment patterns for hepatocellular carcinoma in patients with Child–Pugh class B and their impact on survival: A Korean nationwide registry study
Dongsub Jeon, Gi‐Won Song, Han Chu Lee, Ju Hyun Shim Liver International.2022; 42(12): 2830. CrossRef - Metastatic breast cancer from a hepatocellular carcinoma: a case report
Hyewon Bang, Nam-Hee Kim, Seung Hye Choi, Si Hyun Bae, Eun Sun Jung, Ki Ouk Min, Yong Hwa Eom Korean Journal of Clinical Oncology.2022; 18(2): 93. CrossRef - Current Status and Future Directions of Hepatocellular Carcinoma Surveillance Test Based on Cost-effective Analysis
Jihyun An The Korean Journal of Gastroenterology.2021; 78(5): 255. CrossRef
- A Case of Advanced Hepatocellular Carcinoma with Long-term Post-progression Survival under Repeated Transarterial Chemoembolization after Sorafenib Failure
-
Jihyun Lee, Hwi Young Kim, Yong Jin Jung, Tae Hun Kim, Kwon Yu
-
J Liver Cancer. 2017;17(1):82-87. Published online March 31, 2017
-
DOI: https://doi.org/10.17998/jlc.17.1.82
-
-
Abstract
PDF
- Hepatocellular carcinoma is the third leading cause of cancer related mortality worldwide.
Only 30% of patients are eligible for curative surgical resection at diagnosis. For patients with
advanced hepatocellular carcinoma with accompanying portal vein tumor thrombosis, Sorafenib
is recommended as first-line treatment. However, survival gain from sorafenib is unsatisfactory,
and there is no standard therapy for patients who are intolerable or refractory to sorafenib. Here
we report a case of a 52-year-old man who initially achieved partial response after sorafenib
treatment, but eventually showed disease progression and was treated subsequently with
transarterial chemoembolization (TACE). Multinodular recurrence occurred, but he was treated
with repeated TACE, and has survived for 4 years so far.
|